Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: Real-world data of 13 oncological centers in Portugal

被引：0

作者：

Tomas, T. ^{[1
]}

Nogueira-Costa, G. ^{[2
]}

Eriz, I. ^{[1
]}

Vitorino, M. ^{[3
]}

Baptista, M. Vaz ^{[4
]}

Correia, M. ^{[5
]}

Pereira, T. ^{[6
]}

Oliveira, A. ^{[7
]}

Leal da Costa, L. ^{[8
]}

Pimenta, J. ^{[9
]}

Liu, P. ^{[9
]}

Peixeto, I. ^{[10
]}

Luz, P. ^{[11
]}

Gil, L. ^{[12
]}

Silva, D. ^{[12
]}

Caleca, T. ^{[12
]}

Neves, M. ^{[13
]}

Quintela, A. ^{[14
]}

Monteiro, A. ^{[15
]}

Atalaia, G. ^{[1
]}

Silva, M. ^{[16
]}

Fiuza, T. ^{[16
]}

机构：

[1] Hosp Prof Doutor Fernando da Fonseca, Lisbon, Portugal

[2] Ctr Hosp Barreiro Montijo, Barreiro, Portugal

[3] Hosp Prof Dr Fernando Fonseca, Amadora, Portugal

[4] Hosp Prof Doutor Fernando Fonseca, Lisbon, Portugal

[5] EPE, Hosp Distrital Santarem, Santarem, Portugal

[6] EPE, Inst Portugues Oncol Coimbra Francisco Gentil, Coimbra, Portugal

[7] Hosp Espirito Santo Evora, Evora, Portugal

[8] Hosp Beatriz Angelo, Loures, Portugal

[9] Ctr Hosp Tras Os Montes & Alto Douro, Vila Real, Portugal

[10] EPE, Hosp Geral Santo Antonio, Porto, Portugal

[11] Ctr Hosp Univ Algarve, EPE, Faro, Portugal

[12] EPE, Ctr Hosp Setubal, Setubal, Portugal

[13] Ctr Hosp Lisboa Ocidental, Hosp Sao Francisco Xavier, Lisbon, Portugal

[14] Hosp CUF Descobertas, Lisbon, Portugal

[15] Hosp Vila Franca De Xira, Vila Franca De Xira, Portugal

[16] EPE, Hosp Prof Dr Fernando Fonseca, Amadora, Portugal

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P - 320

引用

页码：88 / 88

页数：1

共 50 条

[1] Real world aspects of palliative trifluridine plus tiperacil (TAS-102) in refractory metastatic colorectal cancer
Wallander, Mikael
Rolander, Bo
Avall-Lundqvist, Elisabeth
Elander, Nils O.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (04) : 616 - +
[2] Neutropenia as a predictor of efficacy in the treatment of metastatic colorectal cancer with TAS-102 (trifluridine - tipiracil).
Rodriguez Garces, Maria Yeray
Senin, Loreto Dominguez
Urbano, Maria Amor
Tarazona, Victoria Avino
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15564 - E15564
[3] A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer
Andersen, Stig E.
Andersen, Ida B.
Jensen, Benny V.
Pfeiffer, Per
Ota, Takayo
Larsen, Jim S.
ACTA ONCOLOGICA, 2019, 58 (08) : 1149 - 1157
[4] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
Kotani, Daisuke
Kuboki, Yasutoshi
Horasawa, Satoshi
Kaneko, Asumi
Nakamura, Yoshiaki
Kawazoe, Akihito
Bando, Hideaki
Taniguchi, Hiroya
Shitara, Kohei
Kojima, Takashi
Tsuji, Akihito
Yoshino, Takayuki
BMC CANCER, 2019, 19 (01)
[5] Safety for trifluridine/tipiracil (TAS-102) with bevacizumab combination in patients with refractory metastatic colorectal cancer in real-world clinical practice: The single-institutional experience.
Yasuda, Kayo
Kotani, Daisuke
Kuboki, Yasutoshi
Fukuoka, Shota
Bando, Hideaki
Kawazoe, Akihito
Nakamura, Yoshiaki
Shitara, Kohei
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[6] Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview
Salvatore, L.
Niger, M.
Bellu, L.
Tamburini, E.
Garcia-Alfonso, P.
Amellal, N.
Delmas, A-S.
Wahba, M.
Prager, G.
ANNALS OF ONCOLOGY, 2016, 27
[7] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
Daisuke Kotani
Yasutoshi Kuboki
Satoshi Horasawa
Asumi Kaneko
Yoshiaki Nakamura
Akihito Kawazoe
Hideaki Bando
Hiroya Taniguchi
Kohei Shitara
Takashi Kojima
Akihito Tsuji
Takayuki Yoshino
BMC Cancer, 19
[8] Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program
Cremolini, Chiara
Rossini, Daniele
Martinelli, Erika
Pietrantonio, Filippo
Lonardi, Sara
Noventa, Silvia
Tamburini, Emiliano
Frassineti, Giovanni Luca
Mosconi, Stefania
Nichetti, Federico
Murgioni, Sabina
Troiani, Teresa
Borelli, Beatrice
Zucchelli, Gemma
Dal Maso, Alessandro
Sforza, Vincenzo
Masi, Gianluca
Antoniotti, Carlotta
Di Bartolomeo, Maria
Miceli, Rosalba
Ciardiello, Fortunato
Falcone, Alfredo
ONCOLOGIST, 2018, 23 (10): : 1178 - 1187
[9] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
Kotani, D.
Kuboki, Y.
Yasuda, K.
Nakamura, Y.
Kawazoe, A.
Bando, H.
Taniguchi, H.
Shitara, K.
Yoshino, T.
ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
[10] Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic.
Grell, Peter
Dvorak, Josef
Vocka, Michal
John, Stanislav
Tuskova, Helena
Buchler, Tomas
Borilova, Simona
Selingerova, Iveta
Vyzula, Rostislav
Petruzelka, Lubos B.
Kiss, Igor
Obermannova, Radka
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →